Immunovant, Inc. — Director's Dealing 2021

Jan 25, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immunovant, Inc. (IMVT)
CIK: 0001764013
Period of Report: 2021-01-22

Reporting Person: Jain Rita (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-22	Common Stock	A	20000	—	Acquired	20000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-22	Stock Option (right to buy)	$42.19	A	220000	Acquired	2031-01-22	Common Stock (220000.0)	Direct

Footnotes

F1: Represents the number of shares underlying restricted stock units awards ("RSUs").

F2: The RSUs vest over four years, with 25% of the RSUs vesting on January 11, 2022 and the remainder of the RSUs vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.

F3: Shares underlying the option vest over four years, with 25% of the shares underlying the option vesting on January 11, 2022, and the remainder of shares underlying the option vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person providing continuous service to the Issuer as of each such date.